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Abstract 
Introduction: The prevalence of depressive disorders in HIV-infected patients ranges from 12% to 
66% and is undiagnosed in 50% to 60% of these patients. Depression in HIV-infected individuals may 
be associated with poor antiretroviral treatment (ART) outcomes, since it may direct influence 
compliance. Objective: To assess the presence of symptoms and risk factors for depression in 
patients on ART. Methods: Cross-sectional study. Certified interviewers administered questionnaires 
and the Beck Depression Inventory (BDI), and participants’ self-reported compliance to ART. 
Clinical and laboratory variables were obtained from clinical records. Patients with BDI ≥ 12 
were defined as depressed. Results: Out of the 250 patients invited to participate, 246 (98%) 
consented. Mean age was 41 ± 9.9 years; most were male (63%). Income ranged from 0-14 Brazilian 
minimum wages. AIDS (CDC stage C) had been diagnosed in 97%, and 81% were in stable immune 
status. One hundred ninety-one (78%) reported compliance, and 161 (68%) had undetectable viral 
loads. The prevalence of depressive symptoms was 32% (95% CI 26-40). In multivariate analysis, 
depressive symptoms were significantly associated with income (prevalence ratio [PR] = 0.85; 
95% CI 0.74-0.97; p = 0.02). Conclusions: Depressive symptoms are frequent in patients on ART, 
and are associated with low income.
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163Depression in patients on HAART
Sintomas depressivos em pacientes infectados pelo HIV tratados por terapia 
antiretroviral altamente ativa
Resumo
Introdução: A prevalência de transtornos depressivos em pacientes infectados pelo HIV 
varia de 12% a 66% e não é diagnosticada em 50% a 60% desses pacientes. A depressão em 
indivíduos HIV positivo pode se associar a resultados fracos do tratamento antirretroviral (TAR) 
porque pode influenciar diretamente a aderência ao regime. Objetivo: Avaliar a presença de 
sintomas e de fatores de risco de depressão em pacientes em TAR. Métodos: Estudo em corte 
transverso. Entrevistadores certificados administraram questionários e o Beck Depression 
Inventory (BDI), e os participantes fizeram o autorrelato da aderência ao TAR. Variáveis clínicas 
e laboratoriais foram obtidas dos prontuários clínicos. Os pacientes com escore ao BDI ≥ 12 
foram definidos como deprimidos. Resultados: Dos 250 pacientes convidados a participar, 246 
(98%) concordaram. A média de idade foi de 41 ± 9,9 anos; a maioria dos pacientes era do sexo 
masculino (63%). A renda variou de 0-14 salários mínimos brasileiros. A AIDS (estágio C dos 
CDC) havia sido diagnosticada em 97% e 81% estavam em estado imune estável. Dos pacientes, 
191 (78%) relataram aderência e 161 (68%) tinham carga viral não detectável. A prevalência 
dos sintomas depressivos foi de 32% (IC 95% 26-40). Em análise multivariada, os sintomas 
depressivos se associaram significativamente à renda (razão de prevalência [RP] = 0,85, IC 95% 
0,74-0,97; p = 0,02). Conclusões: Os sintomas depressivos são frequentes em pacientes em 
TAR e se associam a uma renda baixa.
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Introduction
The prevalence of depression in HIV-infected patients has 
been reported to range from 12% to 66%.1-7 Diagnosing and 
treating these symptoms is critical to improve patients’ 
quality of life; however, 50% to 60% of the cases are not diag-
nosed.8 Psychological stress and progression of HIV infection 
have been associated with a lower quality of life.9 Moreover, 
depression has been associated with poorer adherence to 
antiretroviral treatment (ART).10
Little has been published on the epidemiology of depres-
sion in patients with HIV/AIDS in lower- and middle-income 
countries. The reported prevalence of depressive symptoms 
in patients with HIV/AIDS in those countries range from 8% 
to 60%.11 Despite the variety of instruments used to identify 
depression, it seems to be a neglected public health issue 
in developing countries.11  
The purpose of this study is to report the prevalence of 
depressive symptoms and to identify associated risk factors 
in patients on ART, treated in a specialized HIV/AIDS service 
in southern Brazil, with a particular emphasis on the associa-
tion between depression and ART compliance.
Methods
Design
Cross-sectional study. 
Setting
Reference center for HIV/AIDS-SAE-Pelotas, in Pelotas, Brazil.
Participants
The study population comprised all patients on ART cur-
rently under care at the HIV/AIDS-SAE-Pelotas (N = 800). A 
sample size of 230 was estimated to measure a prevalence 
of depressive symptoms of 30 ± 5%, with 95% confidence 
interval (95%CI).
All patients who attended the clinic for consultation or in 
order to receive prescription drugs were invited to join the 
study. After signing a written informed consent, participants 
were interviewed. The study was approved by the Scientific 
Commission of the Universidade Católica de Pelotas and by 
the Ethics Committee of the Universidade Federal do Rio 
Grande do Sul (number 2003164). 
Trained interviewers administered questionnaires includ-
ing sociodemographic variables and self-reported adherence, 
and administered BDI.12 Clinical and laboratory data were 
obtained from the clinical records. 
Main variables of interest
The presence of depressive symptoms was measured by the 
Beck Depression Inventory (BDI). BDI has 21 items which re-
flect cognitive, affective, behavioral, and somatic symptoms 
of depression. Each item is composed of four statements, and 
the patient is asked to pick the one that best describes how 
he or she has been feeling for the past week. Statements are 
scored on a scale value of 0 to 3, according to the intensity 
of the symptom. Final scores are obtained by adding all 
points. A cutoff point of 12 on BDI score was used to classify 
patients with and without depressive symptoms. Intensity of 
symptoms was classified as mild (12-19), moderate (20-35) 
or severe (36-41).12 
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Compliance was evaluated using participants’ self-reports 
on prescribed antiretrovirals taken in the last three days 
before the interview. A time sheet was used to help patients 
remember their routine activities (e.g., breakfast, lunch) and 
to report the medicines in use, doses and time of administra-
tion. Individual drug compliance was computed dividing the 
number of tablets of each antiretroviral drug taken in three 
days by the number of tablets prescribed in the same days. 
Rate of regimen compliance was calculated by arithmetic 
mean for each drug. Participants were considered compliant 
if they reported taking ≥ 95% of the prescribed doses during 
the three days prior to the evaluation.13,14
Predictor variables
Sex, age, years on ART, household income (as a multiple of 
the Brazilian minimal monthly wage of R$ 350.00, which is 
equivalent to US$ 153.21), employment, receiving social 
security benefits and living situation. The most recent HIV 
plasma viral load prior to the interview was identified from 
clinical records. The lower limit of detection was 50 cop-
ies/mL.13 Other clinical data such as: HIV clinical stage as 
defined by the Centers for Disease Control and Prevention15 
and modified according to the criteria adopted in Rio de 
Janeiro and Caracas;13,15 the CD4 lymphocyte count closest 
to the interview; the ART regimen; and the duration of ART 
treatment were collected from clinical records.  
Statistical analysis
Data were double-entered into EPI-INFO and analyzed in SPSS 
for Windows version 16.0 (SAS Institute, Cary, North Carolina, 
USA). Differences in proportions between patients with or 
without depressive symptoms were tested by the chi-square 
test. Poisson regression analyses with depressive symptoms 
as the outcome variable were carried out to evaluate the 
individual role of risk factors associated with depressive 
symptoms. Variables with p < 0.3 in bivariate analysis were 
included in the multivariable model to estimate the adjusted 
prevalence ratio for depressive symptoms. Risk factors for 
non-compliance were evaluated through Poisson regression 
as well.
Results 
Out of 250 patients invited to participate, 246 (98%) con-
sented. Of these, 154 (63%) were male. The mean age was 
41 ± 9.9 years (range, 18 to 73 years), and income ranged 
from 0 to 14 times the minimum wage (median, 1.90; 1 
MW = R$ 350.00 or US$ 153.51). AIDS was the most preva-
lent clinical stage (97%), and 81% had ≥ 200 CD4 cells/mm. 
One hundred sixty-six (68%) participants had undetectable 
viral load, and 191 (78%) reported being adherent to treat-
ment. Duration of ART ranged from 4 to 139 months (mean 
56.8 ± 34.05), and 55% of participants were using efavirenz 
(EFV). Table 1 presents sociodemographic characteristics of 
HIV-infected patients on ART with and without depressive 
symptoms.
The prevalence of depressive symptoms (BDI score ≥ 12) 
was 32% (95% CI 26%-40%). Overall, 14% classified as having 
mild depressive symptoms, 14% as having moderate depres-
sive symptoms and 4% as having severe depressive symptoms 
(Figure 1). Fatigue (51.2%) and irritability (47.6%) were the 
most frequently reported symptoms. Predictors of depressive 
symptoms in HIV-infected patients on ART are presented in 
Table 1 Sociodemographic characteristics of HIV-infected patients on ART with and without depressive symptoms and 
Relative Risk (RR), SAE-Pelotas, Brazil (N = 246) 
All sample Depressive symptoms RR (CI = 95%) p¹
Yes (n = 79) No (n = 167)
Sex N (%)
Male 154 (62.6) 47 107 0.88 (0.61-1.27) 0.49
Female 92 (37.4) 32 60 1
Age Mean (SD) 41.0 (9.9) 79 167 1.00 (0.99-1.01) 0.68
Years of Study Mean (SD) 6.7 (3.8) 79 167 0.96 (0.92-1.01) 0.14
Income Mean (SD) * 2.1 (1.92) 79 167 0.82 (0.72-0.93) 0.002
Employment N (%)
No steady work 137 (55.7) 53 84 1.62 (1.09-2.41) 0.017
Steady work 109 (44.3) 26 83 1
Receiving any Benefits N (%)
NO 111 (45.1) 30 81 0.75 (0.51-1.09) 0.13
YES 135 (54.9) 49 86 1
Therapeutic regimen containing EFV N (%)
 NO 112 (45.5) 29 83 0.69 (0.47-1.02) 0.061
 YES 134 (54.5) 50 84 1
*In number of minimum wages (R$ 350.00 or US$ 153.51); ¹ Crude Poisson Regression; EFV: efavirenz.
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Such variation may be explained by the different instruments 
used to diagnose depression and by other methodological dif-
ferences, such as the cutoff point used. Different BDI cut points 
have been used; even in their original paper, Beck et al.16 sug-
gested that the choice of an adequate cutoff point depended 
on sample characteristics and study goals. We used 12 as a 
cutoff, which allowed us to identify the largest number of 
patients with symptoms of mild depression or worse.12
EFV is a drug that has been associated with a number of 
neuropsychological side effects and mood disorders.17-19 In a 
randomized clinical trial, Lochet et al.19 found that neuro-
psychiatric adverse reactions associated with EFV occurred 
mainly during the first month of therapy and often persisted 
thereafter. Gutierrez et al.20 studied predictive factors of 
neuropsychiatric adverse events associated with EFV and 
found that the only risk factor associated with central ner-
vous system toxicity, after adjusting for body weight and 
hepatitis C virus co-infection, was EFV plasma concentration.
Considering depressive symptoms, some authors have found 
no association18,21 while others found a high prevalence of 
depression associated with EFV use.19,22 In the present study, 
over half of studied patients were taking an ART regimen 
containing EFV. No association with depressive symptoms was 
found, although a statistically non-significant relative risk 
reduction of 28% for depressive symptoms among patients 
not using EFV was identified. Despite the conflicting results in 
the literature, this finding is important for the evaluation of 
patients already in treatment, since depression may worsen 
adherence23 and contribute to treatment failure.
Participants were considered adherent if they reported 
taking ≥ 95% of the prescribed doses during the three days 
prior to the evaluation.13,14 Those patients under therapeu-
tics regimen including efavirenz were 27% more likely to be 
Figure 1 Distribution of the rate of depressive symptoms 
according to intensity (%).
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Table 2 Multivariable predictors of depressive symptoms 
in HIV-infected patients on ART, SAE-Pelotas, Brazil  
(N = 246)
Prevalence Ratio (CI 95%)*
Adjusted** p
Sex
Male 0.93 (0.64-1.34) p = 0.68
Female 1
Age (years) 1.00 (0.99-1.02) p = 0.73
Years of Study 1.00 (0.95-1.05) p = 0.89
Income (in minimum wages)*** 0.85 (0.74-0.97) p = 0.02
Employment
No steady work 1.38 (0.91-2.11) p = 0.13
With steady work 1
Receiving any benefits
NO 0.72 (0.55-1.2) p = 0.29
YES 1
Therapeutic regimen containing EFV
NO 0.72 (0.48-1.06) p = 0.1
YES 1
* Poisson Regression; ** Adjusted for sex, age, years of study, income, 
employment, receiving any benefit, and therapeutic regimen with 
efavirenz; *** Minimum wage = R$ 350.00 = US$ 153.51; US$ 1 = R$ 2.28; 
EFV: efavirenz; ART: antiretroviral therapy.
Table 3 Multivariable predictors of adherence in HIV-infected 
patients on ART, SAE-Pelotas, Brazil (N = 246)
Prevalence Ratio (CI 95%)*
Adjusted** 
Sex
Male 1  p = 0.87
Female 1.01 (0.88-1.66)
Age (years) 1.00 (0.995-1.008) p = 0.65
Income (in minimum wages)*** 0.85 (0.74-0.97) p = 0.35
Living situation
Alone 1 p = 0.09
Together 1.19 (0.97-1.46)
Time of Treatment 0.999 (0.997-1.00)  p = 0.25
Therapeutic regimen containing EFV 
NO 1  p = 0.002
YES  1.27 (1.09-1.47)
* Poisson Regression; ** Adjusted for sex, age, income, employment, living 
situation, time of treatment and therapeutic regimen with efavirenz; 
*** Minimum wage = R$ 350.00 = US$ 153.51; US$ 1 = R$ 2.28;  Patient 
was considered adherent if reported taking ≥ 95% of the prescribed dose 
during the three days of evaluation; EFV: efavirenz; ART: antiretroviral 
therapy.
Table 2. In multivariate analysis adjusted for sex, age, years 
of education, income, employment, receiving social security 
benefits and therapeutic regimen with efavirenz only income 
remained associated with depressive symptoms (RR = 0.85; 
95% CI 0.74-0.97; p = 0.02). 
Therapeutic regimen containing EFV was independently 
associated with adherence to ART (Table 3).
Discussion
The study showed that 32% of patients had depressive symp-
toms as measured by BDI and their presence was associated 
with low income. Prior studies have shown prevalence of 
depression among HIV-infected patients between 12 to 66%.1-7 
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compliant than patients not taking efavirenz regimen.  This 
might be explained by the fewer tablets needed or lower fre-
quency of doses in therapeutics regimen including efavirenz.
The study has some limitations to be considered. The 
cross-sectional design did not allow us to establish a causal 
relationship between the potential risk factors and the pres-
ence of depressive symptoms. Antidepressant drug use was not 
investigated and may have led to underestimation of depres-
sive symptoms prevalence. Treatment length varied greatly, 
which may have contributed to absence of association between 
depression and clinical stage, since depression is more preva-
lent immediately after the AIDS diagnosis.5 Another limitation 
is the fact that the study was conducted only with HIV-infected 
patients on ART, being most of them stage C (AIDS).
In conclusion, it was found that almost one in three 
patients on ART has depressive symptoms and participants 
presenting symptoms of depression are mostly low-income 
patients. It is suggested that clinicians carefully assess the 
possibility of depressive symptoms in their patients on ART, 
and especially those of lower income. Future studies with 
prospective design, starting at the moment of HIV diagnosis, 
should be able to more clearly explore the causal and tem-
poral relationship between depression, compliance and ART.
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